RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics Despite the recent FDA approval of targeted therapy for BRCA gene mutation (that is, the use of immune checkpoint inhibitor pembrolizumab and Trop-2 antibody drug conjugate), the majority of patients continue to progress after the first two lines of therapy.
Consequenlty, there is an unmet need for patients whose triple-negative breast cancer has progressed despite previous treatment regimens which opens the way for the addition of ONCY's oncolytic virus pelareorep in combination with an immune checkpoint inhibitor.
In June 2020 ONCY announced the opening of a Phase 2 study (IRENE) in triple-negative breast cancer using INCYTE's immune checkpoint inhibitor in combination with ONCY's pelareorep.
In August 2020 ONCY announced the first patient was dosed in the IRENE study.
https://ir.oncolyticsbiotech.com/press-releases/detail/515/oncolytics-biotech-doses-first-patient-in-phase-2-irene
This past week, on November 19, 2021 ONCY announced that the investigators will presenting an update of the IRENE Phase 2 study at SABCS taking place on December 07th.
https://www.prnewswire.com/news-releases/oncolytics-biotech-to-present-phase-2-triple-negative-breast-cancer-trial-update-at-the-2021-san-antonio-breast-cancer-symposium-301428864.html